PAVM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

25.00K

+150%

-0.200

+233.33%

74.00K

+825%

-0.200

+185.71%

98.00K

+1533.33%

-0.190

+280%

Estimates Revision

The market is revising No Change the revenue expectations for PAVmed Inc. (PAVM) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -50.27%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-50.27%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast PAVM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PAVM is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

20.00

Averages

20.00

High

20.00

Current: 0.000

Low

20.00

Averages

20.00

High

20.00

Ascendiant Capital

Edward Woo

Strong Buy

Maintains

$19 → $20

2025-04-21

Reason

Ascendiant Capital

Edward Woo

Price Target

$19 → $20

2025-04-21

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for PAVmed Inc (PAVM.O) is -0.43, compared to its 5-year average forward P/E of -2.73. For a more detailed relative valuation and DCF analysis to assess PAVmed Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.73

Current PE

-0.43

Overvalued PE

2.15

Undervalued PE

-7.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.32

Current EV/EBITDA

-1.62

Overvalued EV/EBITDA

0.18

Undervalued EV/EBITDA

-6.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

62.48

Current PS

22.97

Overvalued PS

165.83

Undervalued PS

-40.87

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PAVM News & Events

Events Timeline

No data

News

8.5

2025-12-30PRnewswire

PAVmed Executes 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing

8.5

2025-12-30Newsfilter

PAVmed Executes 1-for-30 Reverse Stock Split to Maintain Nasdaq Listing

3.5

2025-12-09Newsfilter

Lucid Diagnostics Reports 95% Success Rate in 11,991 EsoGuard Tests for Esophageal Cancer Screening

People Also Watch

Frequently Asked Questions

What is PAVmed Inc (PAVM) stock price today?

The current price of PAVM is 7.29 USD — it has increased 0 % in the last trading day.

What is PAVmed Inc (PAVM)'s business?

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.

What is the price predicton of PAVM Stock?

What is PAVmed Inc (PAVM)'s revenue for the last quarter?

PAVmed Inc revenue for the last quarter amounts to 5.00K USD, decreased -99.50 % YoY.

What is PAVmed Inc (PAVM)'s earnings per share (EPS) for the last quarter?

PAVmed Inc. EPS for the last quarter amounts to -0.29 USD, decreased -120.14 % YoY.

What changes have occurred in the market's expectations for PAVmed Inc (PAVM)'s fundamentals?

How many employees does PAVmed Inc (PAVM). have?

PAVmed Inc (PAVM) has 39 emplpoyees as of January 10 2026.

What is PAVmed Inc (PAVM) market cap?

Today PAVM has the market capitalization of 7.21M USD.